Workflow
SOFTMEDX(00648)
icon
Search documents
京玖康疗(00648)发布中期业绩 股东应占溢利335.3万港元 同比扭亏为盈
智通财经网· 2025-08-18 12:05
Core Viewpoint - 京玖康疗 reported a significant improvement in its financial performance for the first half of 2025, achieving a revenue of HKD 35.77 million, which represents a year-on-year increase of 16.5% and a turnaround from a loss to a profit for shareholders [1] Financial Performance - Revenue reached HKD 35.77 million, marking a 16.5% increase compared to the previous year [1] - Shareholders' profit amounted to HKD 3.353 million, a significant recovery from a loss of HKD 6.093 million in the same period last year [1] - Basic earnings per share were reported at HKD 0.01 [1] Growth Drivers - The revenue growth is attributed to the company's ongoing efforts to expand its product sources and broaden its product portfolio [1]
京玖康疗(00648) - 2025 - 中期财报
2025-08-18 11:51
| 董事會 | 股份代碼 | | --- | --- | | 執行董事 | 648 | | 林品卓 | 註冊辦事處 | | 獨立非執行董事 | 香港 | | | 灣仔軒尼斯道 8-12 號 | | 樂可慰 | 中港大廈 8 樓 | | 唐萃環 | | | 姚俊榮 | 股份過戶登記處 | | 審核委員會 | 卓佳證券登記有限公司 | | | 香港 | | 姚俊榮 ( 主席 ) | 夏慤道 16 號 | | 樂可慰 | 遠東金融中心 17 樓 | | 唐萃環 | | | | 主要銀行 | | 提名委員會 | | | | 中國銀行(香港)有限公司 | | 樂可慰 ( 主席 ) | 香港上海匯豐銀行有限公司 | | 林品卓 | | | 姚俊榮 | 獨立核數師 | | 薪酬委員會 | 容誠(香港) 會計師事務所有限公司 | | | (前稱「先機會計師行有限公司」) | | 姚俊榮 ( 主席 ) | 執業會計師 | | 林品卓 | 註冊公眾利益實體核數師 | | 樂可慰 | | | | 公司網址 | | 風險管理委員會 | | | | www.648.com.hk | | 姚俊榮 ( 主席 ) | | | 林品卓 | | ...
京玖康疗(00648) - 2025 - 中期业绩
2025-08-18 11:48
香港交易及結算所有限公司及香港聯合交易所有限公司「聯交所」 ( ) 對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 簡明綜合財務狀況表 | | | 於 | 年 | 於 年 | | | --- | --- | --- | --- | --- | --- | | | | 6 月 日 | | 6 月 日 | | | 港幣千元 | 附註 | (未經審核 | | ( 經審核 | ) | | 非流動資產 | | | | | | | 物業、廠房及設備 | 10 | | | 67 | | | 使用權資產 | | | | 873 | | | 按公平值計入損益之金融資產 | 11 | | | 3,915 | | | | | | | 4,855 | | | 流動資產 | | | | | | | 存貨 | | | | 4,781 | | | 貿易應收款項 | 12 | | | 16,739 | | | 預付款項、其他應收款項及其他資產 | | | | 19,519 | | | 銀行結餘及現金 | | | | 8,773 | ...
京玖康疗(00648) - 董事会召开日期
2025-08-06 10:00
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣,以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份 時務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港,2025 年 8 月 6 日 於本公告日期,本公司董事會包括林品卓先生為執行董事,及樂可慰先生、唐萃環女士及姚 俊榮先生為獨立非執行董事。 董事會召開日期 京玖醫療健康有限公司(「本公司」)董事會宣佈將於 2025 年 8 月 18 日(星期一)舉行董事會會 議,以批准刊發本公司及其附屬公司截至 2025 年 6 月 30 日之未經審核中期業績。 ...
京玖康疗(00648) - 截至二零二五年七月三十一日止月份之股份发行人的证券变动月报表
2025-08-06 09:52
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致:香港交易及結算所有限公司 | | | | 公司名稱: | 京玖醫療健康有限公司 | | | 呈交日期: | 2025年8月6日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00648 | 說明 | 京玖康療 | | | | | | | | 已發行股份(不包括庫存股份)數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 326,036,828 | | 0 | | 326,036,828 | | 增加 / 減少 (-) | | | 0 ...
京玖康疗(00648.HK)继续停牌 以待达成复牌条件
Ge Long Hui· 2025-07-31 10:53
Core Viewpoint - The company, Jingjiu Kangliao (00648.HK), has received a notification from the Stock Exchange regarding the temporary suspension of delisting procedures, contingent on further developments with the Securities and Futures Commission [1] Group 1: Company Operations - The company primarily engages in the distribution of medical and health equipment and products in Hong Kong, and its operations are continuing as normal in all significant aspects [1] - The board of directors will continue to monitor the impact of the suspension on the company's operations and financial performance, taking appropriate measures as necessary [1] Group 2: Stock Trading Status - The company's shares will remain suspended from trading until the conditions for resumption are met [1] - Shareholders and potential investors are advised to exercise caution when trading the company's shares [1]
京玖康疗(00648) - 復牌之最新资料
2025-07-31 10:44
復牌之最新資料 本公告乃由本公司根據上市規則第 13.24A 條作出,並提述本公司日期為 2025 年4月30日的公告。 本公告所用之詞彙與該公告所界定者具有相同涵義。 復牌進度更新 聯交所於 2020 年 4 月 21 日知會本公司將暫不行使上市規則第 6.01A(2)(b)(i)條權利將本公司除牌, 惟視乎本公司向證監會呈請之進一步發展情況,可能在其認為適當的情況,於較後階段行使上市 規則第 6.01A 條權利。本公司會繼續解決證監會及聯交所的關注。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣,以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份時 務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港,2025 年 7 月 31 日 於本公告日期,本公司董事會包括林品卓先生為執行董事,及樂可慰先生、唐萃環女士及姚俊榮 先生為獨立非執行董事。 本集團主要於香港從事分銷醫療及健康設備及產品之醫療及健康 ...
京玖康疗(00648) - 2025 - 年度业绩
2025-07-17 13:49
[Business Overview](index=1&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) [Core Business and Market Performance](index=1&type=section&id=%E6%A5%AD%E5%8B%99%E6%A6%82%E8%A6%BD) The Group's core business is distributing medical and health equipment in Hong Kong, achieving revenue growth in FY2024 despite margin pressures - The Group primarily distributes medical and health equipment in Hong Kong as an authorized distributor for seven suppliers, generating revenue from equipment sales, consumables, and support services[4](index=4&type=chunk) - In FY2024, the company recorded a **gain on derecognition of liabilities of HK$328 million**, significantly improving its financial position and achieving a positive net asset value[4](index=4&type=chunk) - The Hong Kong medical device market outlook is positive, with **projected growth of 8.3% in 2025** and a **7.6% CAGR from 2025 to 2030**, presenting growth opportunities for the Group[4](index=4&type=chunk) [Financial Analysis](index=2&type=section&id=%E8%B2%A1%E5%8B%99%E6%A6%82%E8%A6%BD) [Operating Performance](index=2&type=section&id=%E8%B2%A1%E5%8B%99%E6%A6%82%E8%A6%BD) The Group's revenue grew by 6.4% to HK$54.6 million in FY2024, but gross profit and margin declined due to a shift in sales mix FY2023-2024 Operating Performance Comparison | Metric | FY2024 | FY2023 | YoY Change | | :--- | :--- | :--- | :--- | | Revenue (HK$) | 54.6 million | 51.3 million | +6.4% | | Gross Profit (HK$) | 18.4 million | 21.1 million | -12.9% | | Gross Margin | 33.7% | 41.1% | -7.4 p.p. | [Annual Profit Analysis](index=2&type=section&id=%E5%B9%B4%E5%BA%A6%E6%BA%A2%E5%88%A9) The Group's comprehensive profit surged to HK$326.3 million in FY2024, driven by a one-off gain and reduced operating expenses - Annual profit surged to **HK$326.3 million**, primarily due to a **one-off gain of HK$328 million from the derecognition of liabilities**[6](index=6&type=chunk) - Administrative expenses **decreased significantly by 35.1% to HK$9.8 million** due to effective cost controls on staff and office expenses[7](index=7&type=chunk) - Financing costs **plummeted by 89.9% to HK$1.3 million** from HK$12.9 million last year, following the implementation of a debt restructuring plan[8](index=8&type=chunk) [Risks and Other Matters](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA%E5%8F%8A%E4%B8%8D%E7%A2%BA%E5%AE%9A%E5%9B%A0%E7%B4%A0) [Key Risks and Uncertainties](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E9%A2%A8%E9%9A%AA%E5%8F%8A%E4%B8%8D%E7%A2%BA%E5%AE%9A%E5%9B%A0%E7%B4%A0) The Group faces multiple risks including macroeconomic uncertainties, market competition, supplier dependency, and potential supply chain disruptions - At the macro level, the Group faces risks from **global economic uncertainty, US-China tensions, and inflation**, which could impact the supply chain[9](index=9&type=chunk) - Operational risks include intense market competition eroding margins, **dependency on key suppliers**, failure to renew distribution rights, and inability to adapt to rapid technological changes[9](index=9&type=chunk)[14](index=14&type=chunk) - The company highlights that maintaining a healthy capital structure is crucial for **going concern**, following past financial challenges[9](index=9&type=chunk) [Post-Reporting Period Events and Share Status](index=3&type=section&id=%E5%A0%B1%E5%91%8A%E6%9C%9F%E5%BE%8C%E4%BA%8B%E9%A0%85) No significant events affecting the Group's operations or finances occurred after the reporting period, and its shares remain suspended from trading - No events with a material impact on the Group occurred after the reporting period[11](index=11&type=chunk) - The company's shares will **continue to be suspended from trading**, and shareholders are advised to exercise caution when dealing in the shares[12](index=12&type=chunk)
京玖康疗(00648) - 2024 - 年度财报
2025-04-28 11:35
Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of HKD 54.6 million, an increase from HKD 51.3 million in 2023, while gross profit decreased to HKD 18.4 million from HKD 21.1 million, resulting in a gross margin of 33.7% compared to 41.1% in the previous year[4]. - The net profit attributable to the company's owners surged to HKD 326.3 million from HKD 12.5 million in 2023, primarily due to a one-time gain from debt restructuring[4]. - The group achieved a net cash inflow from operating activities of HKD 3.9 million, a turnaround from a cash outflow of HKD 4.5 million in 2023[5]. - The total borrowings of the group decreased significantly to HKD 33.1 million from HKD 290.8 million in 2023[5]. - The company reported a significant debt restructuring gain of HKD 328,026,000, compared to no such gain in 2023[118]. - Profit before tax surged to HKD 327,954,000 from HKD 14,369,000, marking an increase of 2,283.5%[118]. - Net profit for the year was HKD 326,317,000, compared to HKD 12,511,000 in 2023, reflecting a substantial increase[118]. - Basic and diluted earnings per share improved to HKD 1.0 from HKD 0.038 in the previous year[118]. - The company reported a pre-tax profit of HKD 327,954,000 for 2024, a substantial increase from HKD 14,369,000 in 2023, reflecting a growth of 2,183%[121]. Assets and Liabilities - As of December 31, 2024, the total assets and net assets of the group were HKD 54.7 million and HKD 2.5 million, respectively, with cash and bank balances of HKD 8.8 million, up from HKD 8.1 million in 2023[5]. - The total assets for the group as of December 31, 2024, amounted to HKD 54,667,000, compared to HKD 56,073,000 in 2023, reflecting a decrease of approximately 2.3%[175]. - The group’s total liabilities as of December 31, 2024, were HKD 52,211,000, a decrease from HKD 379,934,000 in 2023, indicating a significant reduction in liabilities[175]. - The company reported a net asset value of HKD 2,456,000, recovering from a net liability of HKD 323,861,000 in 2023[119]. - Cash and cash equivalents at the end of 2024 increased to HKD 8,773,000 from HKD 8,068,000 in 2023, marking a rise of 8.7%[121]. Corporate Governance - The company has maintained compliance with applicable corporate governance codes and regulations throughout the fiscal year ending December 31, 2024[50][57]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements and found no discrepancies with the auditors[51]. - The company has adopted a board diversity policy that considers factors such as gender, culture, education background, professional experience, skills, knowledge, and tenure for board appointments and re-elections[60]. - All directors are required to retire and stand for re-election every 3 years at the annual general meeting, ensuring a rotation of board members[61]. - The board has established four committees, each with independent authority, to enhance governance and oversight[64]. Employee and Social Responsibility - The group had 19 employees as of December 31, 2024, down from 22 in 2023, with compensation determined based on performance and market conditions[49]. - The company has implemented measures to enhance employee health and safety in response to the COVID-19 pandemic, including regular disinfection of the workplace[96]. - The company has a commitment to training and development, providing comprehensive on-the-job training programs and encouraging participation in external seminars[97]. - The company adheres to labor standards, strictly prohibiting child labor and forced labor, with no serious violations reported during the year[98]. - The company has established a mandatory MPF retirement benefit plan for eligible employees, with contributions calculated as a percentage of basic salary[160]. Environmental, Social, and Governance (ESG) - The company has set up an Environmental, Social, and Governance (ESG) committee to enhance awareness of ESG matters across the group[78]. - The company complies with the Air Pollution Control Ordinance, Wastewater Treatment Ordinance, and Water Pollution Ordinance without any violations reported[84]. - The company has conducted a materiality assessment to identify significant ESG issues relevant to its business and stakeholders[82]. - The company emphasizes the importance of sustainable development and resource conservation in its operations[77]. - The group is committed to sustainable development and aims to create long-term value for society and stakeholders by incorporating environmental factors into its decision-making process[104]. Revenue and Customer Relations - The largest customer accounted for 8.7% of the group's revenue, while the top five customers represented 29.5%[26]. - The largest supplier constituted 42.6% of the group's procurement, with the top five suppliers making up 95.3%[26]. - The group emphasizes the importance of product and service quality as a key competitive advantage, ensuring customer satisfaction through comprehensive training for all service personnel[100]. - The group has not identified any serious violations of laws and regulations related to health and safety, advertising, labeling, and privacy concerning the products and services provided during the year[100]. Financial Reporting and Compliance - The company has adopted accounting policies and applied them consistently to prepare fair and true consolidated financial statements[73]. - The company has not applied any new or revised Hong Kong Financial Reporting Standards that would have a significant impact on its financial position or performance for the current and prior years[124]. - The group assesses tax implications of transactions and records corresponding tax provisions regularly[168]. - The company has confirmed compliance with the standard code for securities trading by all directors for the year ending December 31, 2024[71]. Future Outlook and Strategy - The company plans to focus on organic growth through improved business models, increased market penetration, and product range expansion despite ongoing economic challenges[7]. - The company has no specific major investment or capital asset acquisition plans as of the report date but will continue to seek appropriate investment opportunities[10]. - The group has no significant events occurring after the reporting date[31].
京玖康疗(00648) - 2024 - 年度业绩
2025-03-25 12:41
Financial Performance - For the year ended December 31, 2024, the company reported total revenue of HKD 54,639,000, an increase of 6.4% from HKD 51,340,000 in 2023[3] - The cost of goods sold for 2024 was HKD 36,241,000, compared to HKD 30,215,000 in 2023, resulting in a gross profit of HKD 18,398,000, down 13.0% from HKD 21,125,000[3] - The net profit for the year was HKD 326,317,000, a significant increase from HKD 12,511,000 in 2023[3] - Basic and diluted earnings per share for 2024 were HKD 1.00, compared to HKD 0.038 in 2023[3] - Gross profit for the year was HKD 184 million, down from HKD 211 million in 2023, resulting in a gross margin of 33.7%, compared to 41.1% in the previous year[30] - The net profit attributable to the company's owners was HKD 326.3 million, significantly up from HKD 12.5 million in 2023, primarily due to a one-time gain from debt restructuring[30] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 49,812,000, up from HKD 35,098,000 in 2023[4] - The company reported a net asset value of HKD 2,456,000 in 2024, a recovery from a net liability of HKD 323,861,000 in 2023[4] - The total liabilities of the group as of December 31, 2024, were HKD 52,211,000, with reported segment liabilities of HKD 31,703,000[15] - As of December 31, 2024, total assets were valued at HKD 547 million, a decrease from HKD 561 million in 2023, while net assets were HKD 25 million, compared to a net liability of HKD 323.9 million in 2023[31] - The total borrowings amounted to HKD 33.1 million, down from HKD 290.8 million in 2023, which included HKD 230 million in loans and HKD 60.8 million in bonds payable[31] Operational Highlights - Inventory increased to HKD 4,781,000 in 2024 from HKD 2,830,000 in 2023, indicating a growth of 68.8%[4] - Trade receivables rose significantly to HKD 16,739,000 in 2024 from HKD 7,108,000 in 2023, marking an increase of 135.5%[4] - The adjusted profit before tax for the medical and health segment was HKD 12,265,000 for 2024, compared to HKD 11,308,000 in 2023, reflecting an increase of 8.5%[15] - The average credit period for trade receivables remained at 90 days, with trade receivables increasing to HKD 16.7 million in 2024 from HKD 7.1 million in 2023[25] Debt and Financing - The company recognized a debt restructuring gain of HKD 328,026,000 in 2024, which was not present in 2023[3] - The company incurred financing costs of HKD 1,321,000 in 2024, a significant decrease from HKD 12,940,000 in 2023, indicating improved financial management[19] - The company has no outstanding bonds as of 2024, compared to HKD 60.8 million in 2023[26] Governance and Risk Management - The company has adopted a set of corporate governance principles and practices to ensure effective risk management and internal control systems[39] - A Risk Management Committee was established in April 2023, consisting of two independent non-executive directors and one executive director, to continuously review and monitor the effectiveness of risk management and internal control systems[39] - The Audit Committee has reviewed the group's annual performance for the year ending December 31, 2024, including the accounting principles and practices adopted by the group[41] - The auditors confirmed that the preliminary announcement aligns with the audited consolidated financial statements approved by the board on March 25, 2025[42] Future Outlook - The group plans to focus on improving business models, increasing market penetration, and expanding product ranges to achieve organic growth despite ongoing economic challenges[33] - No capital raising activities were completed during the year ending December 31, 2024[34] - The company will publish its 2024 annual report, which will be sent to shareholders and made available on the company's and the stock exchange's websites[43]